URGN - UroGen Pharma Ltd - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

URGN is currently covered by 5 analysts with an average price target of $25.51. This is a potential upside of $11.47 (81.7%) from yesterday's end of day stock price of $14.04.

UroGen Pharma Ltd's activity chart (see below) currently has 62 price targets and 79 ratings on display. The stock rating distribution of URGN is 97.67% BUY and 2.33% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 19.04% with an average time for these price targets to be met of 36.67 days.

Highest price target for URGN is $50, Lowest price target is $10, average price target is $25.75.

Most recent stock forecast was given by RAGHURAM SELVARAJU from HC WAINWRIGHT on 08-Jul-2025. First documented stock forecast 30-May-2017.

Best performing analysts who are covering URGN - UroGen Pharma Ltd:

Derek Archila Leland Gershell Paul Choi Raghuram Selvaraju Chris Howerton Jason Kolbert

Currently out of the existing stock ratings of URGN, 42 are a BUY (97.67%), 1 are a HOLD (2.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$50

$35.76 (251.12%)

8 days ago
(08-Jul-2025)

0/28 (0%)

$36.29 (264.70%)

Buy

$25

$10.76 (75.56%)

$25

9 days ago
(07-Jul-2025)

0/15 (0%)

$11.51 (85.32%)

Buy

$10

$-4.24 (-29.78%)

$40

1 months 13 days ago
(03-Jun-2025)

2/17 (11.76%)

$5 (100.00%)

42

Hold

$18

$3.76 (26.40%)

$11

1 years 11 months 15 days ago
(31-Jul-2023)

3/8 (37.5%)

$-3.66 (-16.90%)

80

Buy

$10

$-4.24 (-29.78%)

$45

2 years 5 months 8 days ago
(08-Feb-2023)

1/4 (25%)

$0.86 (9.41%)

9

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is URGN (UroGen Pharma Ltd) average time for price targets to be met?

On average it took 36.67 days on average for the stock forecasts to be realized with a an average price target met ratio 19.04

Which analyst has the current highest performing score on URGN (UroGen Pharma Ltd) with a proven track record?

DEREK ARCHILA

Which analyst has the current lower performing score on URGN (UroGen Pharma Ltd) with a proven track record?

JASON KOLBERT

Which analyst has the most public recommendations on URGN (UroGen Pharma Ltd)?

Derek Archila works at WELLS FARGO and has 8 price targets and 5 ratings on URGN

Which analyst is the currently most bullish on URGN (UroGen Pharma Ltd)?

Raghuram Selvaraju with highest potential upside - $35.76

Which analyst is the currently most reserved on URGN (UroGen Pharma Ltd)?

Leland Gershell with lowest potential downside - -$4.24

UroGen Pharma Ltd in the News

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed patient enrollment in its Phase 3 UTOPIA clinical trial of UGN-103 (mitomycin) for intravesical solution, a next-generation formulation in development...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?